LinkedIn co-founder Reid Hoffman grew to become a billionaire when Microsoft purchased LinkedIn in 2016 for $26.2 billion in money, and he has additionally made his fortune on high-return investments in additional than 80 tech startups, together with Airbnb, Groupon, and Flickr. He famously made $111 million from his preliminary $37,500 funding in Fb.
Now Hoffman is popping his consideration to AI in healthcare with a brand new startup he introduced last week with co-founder Dr. Siddhartha Mukherjee: Manas AI. And this time Hoffman has deeper hopes than only a excessive return on funding — he needs to assist remedy most cancers.
Manas is bringing AI to among the world’s prime drug growth scientists to deepen their experience and pace up the speed at which new medication are found. The startup goals to unite researchers with superior AI programs to extra rapidly work out how doubtlessly life-saving medication might work together with the human physique.
Associated: LinkedIn’s Reid Hoffman: To Scale, Do Things That Don’t Scale
Manas is initially turning its consideration to aggressive cancers like breast most cancers, prostate most cancers, and lymphoma. Its long-term imaginative and prescient is to essentially change how the business discovers and develops new medicines.
“Most individuals have had buddies, members of the family, and so on., who’ve died from most cancers or had critical most cancers issues,” Hoffman told CNBC on Monday. “If we will make an enormous distinction on this, and that is the form of factor that AI could make an enormous distinction in, it is the form of cause why AI will be nice for humanity.”
Reid Hoffman The Halfway SF on December 05, 2023, in San Francisco, California. Picture by Kimberly White/Getty Photographs for WIRED
The startup has raised $24.6 million in seed funding to date, with Hoffman main the funding spherical with enterprise capital agency Common Catalyst. It’ll function its AI programs in knowledge facilities owned by Microsoft.
Associated: Reid Hoffman: To Successfully Grow A Business, You Must ‘Expect Chaos’
Mukherjee is a Columbia College professor and writer of “The Emperor of All Maladies,” a e book about most cancers. In 2016, he helped discovered Vor BioPharma, a cell engineering firm, and in 2021 he based Myeloid Therapeutics, a most cancers remedy startup.
Manas presently has 4 staff together with Mukherjee and Hoffman, with Hoffman saying he serves as the corporate’s “AI man” and Mukherjee because the “bio man.” Manas’ purpose is to unite the 2 fields.
“It is not simply one of the best of science and it is not simply one of the best of AI, as a result of both of these two [is] inadequate,” Hoffman informed CNBC. “That you must put these two collectively.”
The AI healthcare sector noticed substantial investments in 2024. Based on PitchBook, traders poured $10.5 billion into 511 healthcare AI offers in 2024. Most cancers screening AI startup Freenome raised probably the most cash out of the group with a $254 million Series F in February 2024.
